Haemonetics FY2025 EPS Forecast Decreased by Zacks Research

Haemonetics Co. (NYSE:HAE) – Analysts at Zacks Research dropped their FY2025 earnings per share (EPS) estimates for shares of Haemonetics in a research note issued to investors on Monday, February 17th. Zacks Research analyst R. Department now expects that the medical instruments supplier will earn $4.56 per share for the year, down from their previous forecast of $4.58. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2025 earnings at $1.23 EPS, Q1 2026 earnings at $1.13 EPS, Q2 2026 earnings at $1.24 EPS, Q4 2026 earnings at $1.36 EPS, FY2026 earnings at $5.06 EPS, Q1 2027 earnings at $1.39 EPS, Q2 2027 earnings at $1.47 EPS and FY2027 earnings at $5.83 EPS.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%.

Other analysts have also recently issued reports about the company. Needham & Company LLC decreased their price objective on Haemonetics from $112.00 to $108.00 and set a “buy” rating on the stock in a report on Friday, February 7th. JMP Securities decreased their price objective on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a report on Friday, February 7th. Bank of America cut Haemonetics from a “neutral” rating to an “underperform” rating and decreased their price objective for the stock from $95.00 to $68.00 in a report on Friday, February 7th. Barrington Research decreased their price objective on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Finally, Raymond James restated a “strong-buy” rating and set a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $101.67.

Haemonetics Stock Down 0.3 %

Shares of HAE opened at $63.88 on Wednesday. The stock has a market capitalization of $3.21 billion, a price-to-earnings ratio of 25.15, a price-to-earnings-growth ratio of 1.09 and a beta of 0.39. Haemonetics has a 1 year low of $58.80 and a 1 year high of $97.97. The business’s 50 day simple moving average is $73.37 and its 200-day simple moving average is $76.85. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55.

Hedge Funds Weigh In On Haemonetics

Hedge funds have recently bought and sold shares of the business. TD Waterhouse Canada Inc. bought a new position in Haemonetics in the 4th quarter valued at $25,000. Covestor Ltd grew its position in Haemonetics by 146.8% in the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock valued at $58,000 after acquiring an additional 439 shares during the last quarter. Whittier Trust Co. bought a new position in Haemonetics in the 4th quarter valued at $62,000. Nisa Investment Advisors LLC grew its position in Haemonetics by 124.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock valued at $92,000 after acquiring an additional 632 shares during the last quarter. Finally, Parkside Financial Bank & Trust grew its position in Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after acquiring an additional 240 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.